Boston Biomedical reports Phase Ib/II data for napabucasin in various cancers

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from various patient populations in a Phase Ib/II trial evaluating twice-daily oral napabucasin (BBI608, BB608) plus paclitaxel to treat advanced malignancies. Data were presented at the American Society of Clinical Oncology meeting in Chicago.

In 98 patients with previously treated platinum-resistant ovarian cancer, napabucasin plus paclitaxel led to an objective response rate (ORR) of 15%. Median progression-free survival (PFS) was 3.3 months and median overall survival (OS) was 9.9 months...